Abstract
is common in cancer. Whether chromothripsis generates actionable
therapeutic targets remains an open question. In a cohort of 64 patients
in blast phase of a myeloproliferative neoplasm (BP-MPN), we describe
recurrent amplification of a region of chromosome 21q (‘chr. 21amp’) in 25%,
driven by chromothripsis in a third of these cases. We report that chr. 21amp
BP-MPN has a particularly aggressive and treatment-resistant phenotype.
DYRK1A, a serine threonine kinase, is the only gene in the 2.7-megabase
minimally amplified region that showed both increased expression and
chromatin accessibility compared with non-chr. 21amp BP-MPN controls.
DYRK1A is a central node at the nexus of multiple cellular functions critical
for BP-MPN development and is essential for BP-MPN cell proliferation
in vitro and in vivo, and represents a druggable axis. Collectively, these
findings define chr. 21amp as a prognostic biomarker in BP-MPN, and link
chromothripsis to a therapeutic target.
| Original language | English |
|---|---|
| Pages (from-to) | 1478-1492 |
| Number of pages | 15 |
| Journal | Nature Genetics |
| Volume | 57 |
| Issue number | 6 |
| Early online date | 9 Jun 2025 |
| DOIs | |
| Publication status | Published - Jun 2025 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver